Benzodiazepine tapering: A prospective study
The DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Benzodiazepines (BZD) are the most widely used sedative-hypnotics, and evidence is rapidly accumulating suggesting potential BZD dependence, association of chronic use with adverse effects and a definite abstinence syndrome produced by withdrawal. AIMS: The present investigation followed prospectively long-term BZD users over 1 year following graded BZD withdrawal in terms of clinical and withdrawal symptoms. METHODS: Clinical symptoms were measured by the Comprehensive Psychopathological Rating Scale (CPRS) and by the Newcastle Anxiety and Depression Diagnostic Index (NADDI) in a sample of BZD users over a 50-week period following graded BZD withdrawal. RESULTS: The results showed that the frequency and severity of clinical symptomatology measured by both scales significantly decreased over time. A detailed analysis of possible patterns of symptoms on both scales revealed four patterns: 1) a gradual decrease over the 50-week time period; 2) an increase in the severity of symptoms at the onset of tapering and a decrease in severity post-tapering; 3) an increase in the severity of symptoms 4 weeks after the cessation of BZD tapering; and 4) no change over the 50-week time period. Rate of BZD withdrawal was associated with CPRS ratings of global illness at admission and at end of treatment, but was not associated with duration or dosage of BZDs, type of BZD, prescriptive and/or non-prescriptive drug use prior to admission, marital status, sex or age. CONCLUSIONS: The results of the present study provide a detailed picture of the pattern of symptoms, their time course and multidimensional determinants of the BZD withdrawal symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients can experience life-threatening withdrawal symptoms with abrupt or rapid discontinuation of BZDs, and some patients experience significant symptoms even with gradual dose reduction.2,20,68”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [68]
In the citing paper
“The population of benzodiazepine patients has been described as a “diagnostically heterogenous group,” which aligns with these results [30,36,40,55,59,65,67].”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [67]
In the citing paper
“The most common indications for benzodiazepine use in these studies were insomnia [30,36,40,55,59,67], generalized anxiety disorder [32,34,45,50,54,65,68], and anxiety with or without panic attacks [30,36,48,54,59,65]”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [67]
In the citing paper
“Symptoms increased in severity when tapering started and increased to 4 wk post-taper, then reduced”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [67]
Citations
Cites
A COMPREHENSIVE PSYCHOPATHOLOGICAL RATING SCALE
Åsberg, M., Montgomery, S. A., Perris, C., Schalling, D., & Sedvall, G. (1978) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1978.tb02357.x · Cited by 1,326
The Diagnosis of Depressive Syndromes and the Prediction of E.C.T. Response
Carney, M. W. P., Roth, M., & Garside, R. F. (1965) · British Journal of Psychiatry · doi:10.1192/bjp.111.477.659 · Cited by 936
Jerram, T. C. (1981) · Side Effects of Drugs Annual · doi:10.1016/s0378-6080(81)80009-8 · Cited by 690
Drugs and the treatment of psychiatric disorders
Baldessarini, R. J. (1996) · Medical Entomology and Zoology · Cited by 683
Benzodiazepine use, abuse, and dependence.
O’Brien, C. P. (2005) · PubMed · Cited by 539
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455
Withdrawal Reaction after Long-Term Therapeutic Use of Benzodiazepines
Busto, U., Sellers, E. M., Naranjo, C. A., Cappell, H., Sanchez-Craig, M., & Sykora, K. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610023151403 · Cited by 369
Benzodiazepine withdrawal: an unfinished story.
Ashton, H. (1984) · BMJ · doi:10.1136/bmj.288.6424.1135 · Cited by 291
Hypnotics and sedatives; ethanol
Wr, H. (1996) · Medical Entomology and Zoology · Cited by 275
Gradual Withdrawal of Diazepam after Long-Term Therapy
Tyrer, P., Owen, R., & Dawling, S. (1983) · The Lancet · doi:10.1016/s0140-6736(83)92355-3 · Cited by 271
Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.7.848 · Cited by 176
Protracted withdrawal syndromes from benzodiazepines
Ashton, H. (1991) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(91)90023-4 · Cited by 170
Schweizer, E. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810290060012 · Cited by 138
History of benzodiazepine dependence
LADER, M. H. (1991) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(91)90027-8 · Cited by 129
The Pharmacological Basis of Therapeutics, 8th Edition
Nahorski, S. R. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90055-d · Cited by 126 · cited 2×
“(6, 7) in terms of reduction or control of anxiety-related symptoms, and in terms of decreased risk of suicide because of their low toxicity (6, 8–1l).”
BackgroundLong-term treatment of social phobia with clonazepam.
Davidson, J. R., Ford, S. M., Smith, R. D., & Potts, N. L. S. (1991) · PubMed · Cited by 116
Maintenance Drug Treatment for Panic Disorder: II. Short- and Long-term Outcome After Drug Taper
Rickels, K. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820130067010 · Cited by 94
LADER, M., & MORTON, S. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01831.x · Cited by 93
Long-term benzodiazepine users 3 years after participation in a discontinuation program
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.757 · Cited by 87
Toxicity and Adverse Consequences of Benzodiazepine Use
Ashton, H. (1995) · Psychiatric Annals · doi:10.3928/0048-5713-19950301-09 · Cited by 73
ASHTON, H., & GOLDING, J. F. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb00611.x · Cited by 69
Withdrawal from long-term benzodiazepine use: randomised trial in family practice.
(2006) · PubMed Central · Cited by 67
Differential Efficacy of Unilateral and Bilateral ECT
FONTAINE, R., & YOUNG, T. (1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.8.1013-b · Cited by 62
Effects of amperozide in schizophrenia
Axelsson, R., Nilsson, A., Christensson, E., & Björk, A. (1991) · Psychopharmacology · doi:10.1007/bf02246025 · Cited by 59
In‐patient benzodiazepine withdrawal: comparison of fixed and symptom‐triggered taper methods
MCGREGOR, C., MACHIN, A., & WHITE, J. M. (2003) · Drug and Alcohol Review · doi:10.1080/09595230100100615 · Cited by 49
Ladewig, D. (1983) · Pharmacopsychiatry · doi:10.1055/s-2007-1017458 · Cited by 49
Pharmacologic aspects of benzodiazepine tolerance and dependence
Busto, U., & Sellers, E. M. (1991) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(91)90024-5 · Cited by 48
LADER, M. H., & Russell, J. (1993) · Addiction · doi:10.1111/j.1360-0443.1993.tb02046.x · Cited by 47
HARZER, K., & Barchet, R. (1977) · Journal of Chromatography A · doi:10.1016/s0021-9673(00)93773-7 · Cited by 42
Tönne, U., Hiltunen, A. J., Vikander, B., Engelbrektsson, K., Bergman, H., Bergman, I., Leifman, H., & Borg, S. (1995) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1995.tb09786.x · Cited by 40
Self-citationFindings From Self-Administration Research on the Addiction Potential of Benzodiazepines
Roache, J. D., & Meisch, R. A. (1995) · Psychiatric Annals · doi:10.3928/0048-5713-19950301-08 · Cited by 36
The prolonged benzodiazepine withdrawal syndrome: anxiety or hysteria?
Higgitt, A., Fonagy, P., Toone, B., & Shine, P. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb01375.x · Cited by 35
Factors Predicting Long-Term Outcome after Chronic Benzodiazepine Therapy
Holton, A., Riley, P., & Tyrer, P. (1992) · Journal of Affective Disorders · doi:10.1016/0165-0327(92)90109-j · Cited by 33
The interrater reliability of a Dutch version of the Comprehensive Psychopathological Rating Scale
Goekoop, J. G., Klein, E. A. M. K. D., Hoeksema, T., Klinkhamer, R. A., Gaalen, H. A. E. V., & Velde, E. A. V. D. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb05525.x · Cited by 29
Bertschy, G., Viel, J., & Ahyi, R. (1992) · Journal of Affective Disorders · doi:10.1016/0165-0327(92)90003-o · Cited by 25
Abuse, Addiction, Tolerance, and Dependence to Benzodiazepines in Medical and Nonmedical Populations
Miller, N. S., & Gold, M. S. (1991) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952999108992807 · Cited by 25
Zimmerman, M. B., Coryell, W. H., PFOHL, B. M., & Stangl, D. K. (1987) · The British Journal of Psychiatry · doi:10.1192/bjp.150.4.526 · Cited by 19
Zimmerman, M. B., PFOHL, B. M., Stangl, D. K., & Coryell, W. H. (1986) · The British Journal of Psychiatry · doi:10.1192/bjp.149.5.627 · Cited by 18
Epidemiology of Benzodiazepine Use and Dependence
Gold, M. S., Miller, N. S., Stennie, K., & Populla-Vardi, C. (1995) · Psychiatric Annals · doi:10.3928/0048-5713-19950301-06 · Cited by 18
Liability and Efficacy From Long-Term Use of Benzodiazepines: Documentation and Interpretation
Miller, N. S. (1995) · Psychiatric Annals · doi:10.3928/0048-5713-19950301-10 · Cited by 16
An assessment of the Newcastle Anxiety Depression Index
Davidson, J. R. T., Pelton, S., Krishnan, K. R. R., McLeod, M. N., Raft, D. D., Miller, R. D., & Allf, B. (1986) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1986.tb02722.x · Cited by 7
Lithium discontinuers. II. Therapeutic outcome
Nilsson, A., & Axelsson, R. (1991) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1991.tb01424.x · Cited by 6
The Practical Business of Treatment
Edwards, G. (1989) · British Journal of Addiction · doi:10.1111/j.1360-0443.1989.tb03450.x · Cited by 5
Tönne, U., Hiltunen, A. J., Engelbrektsson, K., Björvell, H., Vikander, B., & Borg, S. (1998) · Personality and Individual Differences · doi:10.1016/s0191-8869(97)00242-0 · Cited by 2
Self-citation
Research works printed but not linked: 5
- Balter MB, 1991, J Clin Psychiat, 52, 16
- O’Brien CP, 2005, J Clin Psychiatry, 66, 28
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 3rd edition-revised. Washington, DC: The American Psychiatric Association; 1987.
- Schuetz H, 1982, Aerztliches Laborator, 28, 117
- Vicens C, 2006, Br J Gen Pract, 56, 958
Cited by
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
“A recent prospective study revealed four patterns of withdrawal symptoms over time [131]: 1 a gradual decrease over the 50-week time-period; 2 an increase in the severity of symptoms at the onset of tapering and a decrease in severity post-tapering; 3 an increase in the severity of symptoms 4 weeks after the cessation…”
BackgroundBenzodiazepine harm: how can it be reduced?
Lader, M. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04418.x · Cited by 359
Dell’osso, B., & Lader, M. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2011.11.003 · Cited by 210
“A recent prospective study revealed four patterns of withdrawal symptoms over time [177]: a gradual decrease over the 50-week time period; an increase in the severity of symptoms at the onset of tapering and a decrease in severity post-tapering; an increase in the severity of symptoms 4 weeks after the cessation of BZ…”
BackgroundWithdrawing Benzodiazepines in Patients With Anxiety Disorders
Lader, M., & Kyriacou, A. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0642-5 · Cited by 67
Brunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
“2,20,68 As such, it is important for clinicians to adopt a patient-centered approach when considering BZD tapering, acknowledging patient concerns and engaging in a shared decision-making process.”
Metadata
- Authors
- Vikander, B., Koechling, U. M., Borg, S., Tönne, U., & Hiltunen, A. J.
- Affiliations
- Karolinska Institutet (SE)
- Karlstad University (SE)
- Corresponding author
- Hiltunen, Arto J.
- Venue
- Nordic Journal of Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2010-07-15
- Volume
- 64
- Issue
- 4
- Pages
- 273-282
- ISSN
- 0029-1455 (ISSN-L)
- 0803-9488
- 1502-4725
- OpenAlex
- W2103482466
- Cited by
- 37
- References
- 45
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 3 · 2021: 4 · 2020: 1 · 2019: 4 · 2018: 2 · 2017: 4 · 2016: 1 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 3
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nordic Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- benzodiazepine withdrawal, benzodiazepine tapering, withdrawal symptoms, benzodiazepine dependence, sedative-hypnotic drugs, Comprehensive Psychopathological Rating Scale
- MeSH terms
- Adolescent, Adult, Anxiety Disorders, Benzodiazepines, Depressive Disorder, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Hypnotics and Sedatives, Male, Middle Aged, Prospective Studies, Severity of Illness Index, Substance Withdrawal Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.